Christopher Whitmore

Christopher Whitmore is an accomplished financial executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Chief Financial Officer at Ray Therapeutics, Inc. since September 2024, Christopher has held similar positions at Immune-Onc Therapeutics, Notable, and Harpoon Therapeutics. Prior roles include Vice President of Finance & Administration at Immune Design and Corporate Controller/Senior Director of Finance at AcelRx Pharmaceuticals, Inc. Christopher began a career in finance at KPMG LLP, where a managerial role in audit provided foundational experience. Christopher holds a BA in Business, Economics, Accounting, and Sports Management from UC Santa Barbara.